Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 2
2008 3
2009 5
2010 7
2011 4
2012 4
2013 4
2014 5
2015 4
2016 4
2017 4
2018 3
2019 4
2020 6
2021 9
2022 17
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries.
MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, Plass K, Ribal MJ, Roobol MJ, Nieboer D, Schouten N, Skolarus TA, Smith EJ, N'Dow J, Mottet N, Briganti A; Pan-European National Urological Society IMAGINE Collaborative (see Supplemental material for group members affiliations):. MacLennan S, et al. Eur Urol. 2023 May;83(5):393-401. doi: 10.1016/j.eururo.2022.12.031. Epub 2023 Jan 11. Eur Urol. 2023. PMID: 36639296 Free article.
PARP inhibitors in advanced prostate cancer: when to use them?
Díaz-Mejía N, García-Illescas D, Morales-Barrera R, Suarez C, Planas J, Maldonado X, Carles J, Mateo J. Díaz-Mejía N, et al. Among authors: planas j. Endocr Relat Cancer. 2021 Jul 15;28(8):T79-T93. doi: 10.1530/ERC-21-0133. Endocr Relat Cancer. 2021. PMID: 34256353 Review.
The present and future of prostate cancer urine biomarkers.
Rigau M, Olivan M, Garcia M, Sequeiros T, Montes M, Colás E, Llauradó M, Planas J, Torres Id, Morote J, Cooper C, Reventós J, Clark J, Doll A. Rigau M, et al. Among authors: planas j. Int J Mol Sci. 2013 Jun 17;14(6):12620-49. doi: 10.3390/ijms140612620. Int J Mol Sci. 2013. PMID: 23774836 Free PMC article. Review.
Role of immunotherapy in castration-resistant prostate cancer (CRPC).
Suárez C, Morales-Barrera R, Ramos V, Núñez I, Valverde C, Planas J, Morote J, Maldonado X, Carles J. Suárez C, et al. Among authors: planas j. BJU Int. 2014 Mar;113(3):367-75. doi: 10.1111/bju.12110. Epub 2013 Apr 12. BJU Int. 2014. PMID: 23650874 Review.
Relationship between Proclarix and the Aggressiveness of Prostate Cancer.
Campistol M, Triquell M, Regis L, Celma A, de Torres I, Semidey ME, Mast R, Mendez O, Planas J, Trilla E, Morote J. Campistol M, et al. Among authors: planas j. Mol Diagn Ther. 2023 Jul;27(4):487-498. doi: 10.1007/s40291-023-00649-y. Epub 2023 Apr 20. Mol Diagn Ther. 2023. PMID: 37081322
A risk-organised model for clinically significant prostate cancer early detection.
Morote J, Borque-Fernando Á, Triquell M, Abascal JM, Servian P, Planas J, Mendez O, Esteban LM, Tilla E. Morote J, et al. Among authors: planas j. BJUI Compass. 2023 Mar 7;4(4):420-422. doi: 10.1002/bco2.230. eCollection 2023 Jul. BJUI Compass. 2023. PMID: 37334020 Free PMC article. No abstract available.
The Barcelona Predictive Model of Clinically Significant Prostate Cancer.
Morote J, Borque-Fernando A, Triquell M, Celma A, Regis L, Escobar M, Mast R, de Torres IM, Semidey ME, Abascal JM, Sola C, Servian P, Salvador D, Santamaría A, Planas J, Esteban LM, Trilla E. Morote J, et al. Among authors: planas j. Cancers (Basel). 2022 Mar 21;14(6):1589. doi: 10.3390/cancers14061589. Cancers (Basel). 2022. PMID: 35326740 Free PMC article.
76 results